EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer



RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer



Cancer Biomarkers 10(1): 13-26



Breast cancer is the most common cancer in women worldwide, representing 28.2% of all female malignancies. In addition to genetic changes, epigenetic events, as aberrant DNA methylation and histone modification, are responsible for cancer development. Many tumour suppressor genes are inactivated by DNA hypermethylation, which could be utilized for identification of new epigenetic biomarkers. To investigate the relation between DNA methylation level and breast cancer progression, we analysed DNA methylation in RASSF1A and CDH1 promoters using quantitative multiplex methylation-specific PCR in paraffin-embedded tumour tissues and blood samples from 92 breast cancer patients and 50 controls, respectively. The associations between RASSF1A and CDH1 methylation levels and clinico-pathological parameters were tested by Kruskal-Wallis and van der Waerden ANOVA tests. Out of 92 breast cancer patients, 76 (82.6%) manifested various levels of RASSF1A (range from 1.20 to 92.63%) and 20 (21.7%) of CDH1 (range from 1.20 to 79.62%) methylation. However, no methylation was found in 50 controls. Increasing trends in RASSF1A methylation were observed in tumour size, lymph node status and TNM stage, but only CDH1 methylation levels showed statistically significant differences between the patient subgroups in lymph node status and IHC subtype. Overall, stable relatively high RASSF1A methylation could be utilised as universal tumour marker and the less frequent but highly methylated CDH1 promoter can serve for identification of potentially metastasising tumours.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333474

Download citation: RISBibTeXText

PMID: 22297548

DOI: 10.3233/CBM-2012-0230



Related references

Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer. Oncology Reports 30(6): 2878-2886, 2014

Potential role of promoter region hypermethylation of RASSF1A, APC, H-Cadherin or Cyclin D2 for breast cancer risk assessment. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1039, March, 2002

Role of physical activity in modulating breast cancer risk as defined by APC and RASSF1A promoter hypermethylation in nonmalignant breast tissue. Cancer Epidemiology, Biomarkers & Prevention 16(2): 192-196, 2007

Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 1(2): 88-93, 2007

CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. Bmc Cancer 6(): 48-48, 2006

High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer. Pathology 37(2): 125-130, 2005

Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer. Molecular Carcinogenesis 52(6): 475-487, 2013

Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Research 15(1): R4-R4, 2015

Promoter hypermethylation of the tumor suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. 2013

Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Research 15(1), 2013

Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients. Iranian Biomedical Journal 13(4): 199-206, 2010

Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients. Journal of Molecular Medicine 93(8): 917-934, 2016

Relationship between the expression of RASSF1A protein and promoter hypermethylation of RASSF1A gene in bladder tumor. Journal of Huazhong University of Science and Technology. Medical Sciences 28(2): 182-184, 2008

Role of RASSF1A hypermethylation in prostate cancer. Zhonghua Nan Ke Xue 13(9): 822-825, 2007

Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients. Life Sciences 82(25-26): 1288-1292, 2008